RxDoctor Payments Data

Melissa Mefford, MD

Family Medicine · Vevay, INNPI 1629431499

Payments from drug & device makers

$503in general payments, 2019–2025

Across 32 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$144
  • Novo Nordisk$96
  • AbbVie$85
  • Otsuka America Pharmaceutical, Inc.$67
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$46
  • Dexcom, Inc.$15
  • plus $50 from 4 others

What the payments were for

  • Food & beverage$503100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$503 in reported general payments places this provider in the 45th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$51,807
Medicare patients
104
Services billed
609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$94,498
JardianceEmpagliflozin41$64,389
MounjaroTirzepatide36$51,072
EliquisApixaban28$25,813
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$24,022
XareltoRivaroxaban13$21,646
FarxigaDapagliflozin Propanediol15$16,417
TrintellixVortioxetine Hydrobromide17$14,720
Breo ElliptaFluticasone/Vilanterol33$13,199
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$9,245
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$6,237
OxycontinOxycodone Hcl12$6,147
SymbicortBudesonide/Formoterol Fumarate14$6,054
Spiriva RespimatTiotropium Bromide11$5,634
Arnuity ElliptaFluticasone Furoate11$3,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$96$94,49866 claims
Lilly USA, LLCMounjaro$144$51,07236 claims
PfizerEliquis$11$25,81328 claims
AstraZenecaFarxiga, Symbicort$12$22,47129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Vevay

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →